- Home
- ALVO vs JANX Comparison
ALVO vs JANX Comparison
Compare ALVO & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALVO | JANX |
|---|---|---|
| Founded | 2013 | 2017 |
| Country | Luxembourg | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.8B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | ALVO | JANX |
|---|---|---|
| Price | $5.11 | $34.01 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 11 |
| Target Price | $10.67 | ★ $77.40 |
| AVG Volume (30 Days) | 820.8K | ★ 1.1M |
| Earning Date | 11-12-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.24 | N/A |
| Revenue | ★ $573,350,000.00 | $10,000,000.00 |
| Revenue This Year | $34.94 | N/A |
| Revenue Next Year | $39.55 | $89.91 |
| P/E Ratio | $21.24 | ★ N/A |
| Revenue Growth | ★ 45.55 | N/A |
| 52 Week Low | $4.70 | $21.73 |
| 52 Week High | $13.70 | $71.71 |
Technical Indicators
Market Signals| Indicator | ALVO | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 33.90 | 70.08 |
| Support Level | $5.05 | $28.25 |
| Resistance Level | $5.49 | $35.34 |
| Average True Range (ATR) | 0.28 | 2.00 |
| MACD | 0.08 | 0.56 |
| Stochastic Oscillator | 6.87 | 88.56 |
Price Performance
Historical ComparisonAbout ALVO Alvotech
Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.